keyword
MENU ▼
Read by QxMD icon Read
search

predictive biomarker bevacizumab

keyword
https://www.readbyqxmd.com/read/28819189/vascular-hysteresis-loops-and-vascular-architecture-mapping-in-patients-with-glioblastoma-treated-with-antiangiogenic-therapy
#1
Andreas Stadlbauer, Max Zimmermann, Stefan Oberndorfer, Arnd Doerfler, Michael Buchfelder, Gertraud Heinz, Karl Roessler
In this study, we investigated the variability of vascular hysteresis loop (VHL) shapes and the spatial heterogeneity of neovascularization and microvascular alterations using vascular architecture mapping (VAM) in patients with recurrent glioblastoma during bevacizumab mono-therapy. VAM data were acquired in 13 patients suffering from recurrent glioblastoma prior to and 3 months after bevacizumab treatment onset using a dual contrast agent injections approach as part of routine MRI. Two patients were additionally examined after the first cycle of bevacizumab to check for early treatment response...
August 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28814907/new-prognostic-biomarkers-and-therapeutic-effect-of-bevacizumab-for-patients-with-non-small-cell-lung-cancer
#2
Maiko Niki, Takashi Yokoi, Takayasu Kurata, Shosaku Nomura
BACKGROUND: Several biomarkers have emerged as potential prognostic and predictive markers for non-small-cell lung cancer (NSCLC). Successful inhibition of angiogenesis with the antivascular endothelial growth factor antibody, bevacizumab, has improved the efficacy seen with standard cytotoxic therapy of NSCLC. However, despite such enhanced treatment strategies, the prognosis for patients with advanced NSCLC remains poor. PATIENTS AND METHODS: We assessed potential biomarkers in 161 NSCLC patients and 42 control patients...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28814275/randomized-study-comparing-full-dose-monotherapy-s-1-followed-by-irinotecan-and-reduced-dose-combination-therapy-s-1-oxaliplatin-followed-by-s-1-irinotecan-as-initial-therapy-for-older-patients-with-metastatic-colorectal-cancer-nordic-9
#3
Stine Braendegaard Winther, Pia Österlund, Åke Berglund, Bengt Glimelius, Camilla Qvortrup, Halfdan Sorbye, Per Pfeiffer
BACKGROUND: Metastatic colorectal cancer (mCRC) is a disease of older age, but there is a relative lack of knowledge about effects of chemotherapy in older patients as they are under-represented in clinical trials. Little data can guide whether the strategy in older mCRC patients should be a sequential full-dose monotherapy chemotherapy approach or a dose-reduced combination chemotherapy approach. The oral 5FU prodrug S-1 seems to have less side effects than capecitabine and should be an optimal drug for older patients, but few data are available...
August 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28774461/phase-ii-trial-of-bevacizumab-with-dose-dense-paclitaxel-as-first-line-treatment-in-patients-with-advanced-ovarian-cancer
#4
Nicole D Fleming, Robert L Coleman, Celestine Tung, Shannon N Westin, Wei Hu, Yunjie Sun, Priya Bhosale, Mark F Munsell, Anil K Sood
OBJECTIVES: To assess the tolerability and efficacy of bevacizumab with carboplatin and weekly paclitaxel as first-line adjuvant therapy for advanced stage ovarian cancer. METHODS: After IRB approval, this single-institution, phase II study enrolled patients with stage III or IV epithelial ovarian cancer after primary cytoreductive surgery to treatment with carboplatin (AUC 5), weekly paclitaxel (80mg/m2), and bevacizumab (15mg/kg) every 3weeks for at least 6cycles...
July 31, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28730771/biomarkers-for-the-early-detection-of-relapses-in-metastatic-colorectal-cancers
#5
Gabriela Chereches, Otilia Barbos, Rares Buiga, Ovidiu Balacescu, Dana Iancu, Nicolae Todor, Loredana Balacescu, Nicu Miron, Nona Bejinariu, Tudor-Eliade Ciuleanu
PURPOSE: To assess prognostic/predictive value of carcinoembryonic antigen (CEA), transthyretin (TRT), αenolase (NNE), β2-microglobulin (β2-micro), B-cell activating factor (BAFF) and circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) patients treated with chemotherapy with or without bevacizumab. METHODS: 72 histologically confirmed mCRC patients treated at Oncology Institute Cluj were included. Biomarker levels were measured through validated methods...
May 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28721500/early-prediction-of-tumor-response-to-bevacizumab-treatment-in-murine-colon-cancer-models-using-three-dimensional-dynamic-contrast-enhanced-ultrasound-imaging
#6
Jianhua Zhou, Huiping Zhang, Huaijun Wang, Amelie M Lutz, Ahmed El Kaffas, Lu Tian, Dimitre Hristov, Jürgen K Willmann
Due to spatial tumor heterogeneity and consecutive sampling errors, it is critically important to assess treatment response following antiangiogenic therapy in three dimensions as two-dimensional assessment has been shown to substantially over- and underestimate treatment response. In this study, we evaluated whether three-dimensional (3D) dynamic contrast-enhanced ultrasound (DCE-US) imaging allows assessing early changes in tumor perfusion following antiangiogenic treatment (bevacizumab administered at a dose of 10 mg/kg b...
July 18, 2017: Angiogenesis
https://www.readbyqxmd.com/read/28714375/the-association-of-mir-126-3p-mir-126-5p-and-mir-664-3p-expression-profiles-with-outcomes-of-patients-with-metastatic-colorectal-cancer-treated-with-bevacizumab
#7
Ondrej Fiala, Pavel Pitule, Petr Hosek, Vaclav Liska, Ondrej Sorejs, Jan Bruha, Ondrej Vycital, Tomas Buchler, Alexandr Poprach, Ondrej Topolcan, Jindrich Finek
MicroRNAs regulate the expression of genes involved in several important cancer-related processes including cell adhesion, proliferation, and tumour angiogenesis. Bevacizumab is routinely used in the treatment of patients with metastatic colorectal cancer, but, so far, no reliable biomarker predicting response to bevacizumab has been established. The aim of our retrospective study was to evaluate the association of miR-126-3p, miR-126-5p and miR-664-3p tumour expression levels with outcomes of patients with metastatic colorectal cancer treated with bevacizumab...
July 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28712098/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-1-biologic-therapies-targeting-the-epidermal-growth-factor-receptor-and-vascular-endothelial-growth-factor
#8
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
The survival of patients with metastatic colorectal cancer has improved dramatically in recent years, with overall survival exceeding 3 years in large randomized clinical trials. There are now several treatment options for patients with metastatic colorectal cancer. In addition to chemotherapy backbones utilizing fluoropyrimidine, oxaliplatin, and irinotecan combinations, biologic agents that target specific oncogenic pathways have contributed to the improved survival observed in this patient population. This class of medications includes epidermal growth factor receptor (EGFR)-targeted drugs (cetuximab and panitumumab) and vascular endothelial growth factor (VEGF)-targeted therapies (bevacizumab, ramucirumab, ziv-aflibercept, and regorafenib)...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28693229/micrornas-as-outcome-predictors-in-patients-with-metastatic-colorectal-cancer-treated-with-bevacizumab-in-combination-with-folfox
#9
I Kiss, J Mlčochová, K Součková, P Fabian, A Poprach, J Halamkova, M Svoboda, R Vyzula, O Slaby
Bevacizumab is a humanized anti-vascular endothelial growth factor monoclonal antibody, used in combination with a oxaliplatin-based chemotherapy in the treatment of metastatic colorectal cancer (mCRC). The aim of the present study was to identify microRNA (miRNA)-based predictive biomarkers of therapy response in order to avoid unnecessary and costly therapy to non-responding patients. High-throughput miRNA microarray profiling (Affymetrix miRNA array) was performed on a discovery cohort of patients with mCRC...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28690648/recent-advances-in-the-neoadjuvant-treatment-of-breast-cancer
#10
REVIEW
Gábor Rubovszky, Zsolt Horváth
In the last few decades, neoadjuvant therapy for breast cancer has gained considerable therapeutic importance. Despite extensive clinical investigations, it has not yet been clarified whether neoadjuvant therapy would result in improved survival in comparison with the standard adjuvant setting in any subgroups of patients with breast cancer. Chemotherapy is especially effective in the treatment of endocrine insensitive tumors, and such ther-apeutic benefit can be assumed for patients with triple-negative, or hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-positive breast cancer...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28655794/diffusion-mri-phenotypes-predict-overall-survival-benefitfrom-anti-vegf-monotherapy-in-recurrent-glioblastoma-converging-evidence-from-phase-ii-trials
#11
Benjamin M Ellingson, Elizabeth Gerstner, Marion Smits, Raymond Y Huang, Rivka R Colen, Lauren E Abrey, Dana T Aftab, Gisela M Schwab, Colin Hessel, Robert J Harris, Ararat Chakhoyan, Renske Gahrmann, Whitney B Pope, Kevin Leu, Catalina Raymond, Davis C Woodworth, John F de Groot, Patrick Y Wen, Tracy Batchelor, Martin J van den Bent, Timothy F Cloughesy
Anti-VEGF therapies remain controversial in the treatment of recurrent glioblastoma (GBM). In the current study we demonstrate that recurrent GBM patients with a specific diffusion MR imaging signature have an overall survival (OS) advantage when treated with cediranib, bevacizumab, cabozantinib, or aflibercept monotherapy at first or second recurrence. These findings were validated using a separate trial comparing bevacizumab with lomustine. <br /><br />Experimental Design: Patients with recurrent GBM and diffusion MRI from the monotherapy arms of 5 separate Phase II clinical trials were included: 1) cediranib (NCT00035656); 2) bevacizumab (BRAIN Trial, AVF3708g; NCT00345163); 3) cabozantinib (XL184-201; NCT00704288); 4) aflibercept (VEGF Trap; NCT00369590); and 5) bevacizumab or lomustine (BELOB; NTR1929)...
June 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28654630/prognostic-value-of-subretinal-hyperreflective-material-in-neovascular-age-related-macular-degeneration-treated-with-bevacizumab
#12
Russell Pokroy, Michael Mimouni, Edward Barayev, Fani Segev, Noa Geffen, Arie Y Nemet, Ori Segal
PURPOSE: To study the correlation between subretinal hyperreflective material (SHRM) seen on spectral domain optical coherence tomography at baseline and visual outcomes after intravitreal bevacizumab injection in neovascular age-related macular degeneration. METHODS: Consecutive patient charts with treatment-naive center-involved neovascular age-related macular degeneration treated with 3 monthly intravitreal bevacizumab's, continued as needed, from 2011 to 2014 were reviewed...
June 20, 2017: Retina
https://www.readbyqxmd.com/read/28654140/epidermal-growth-factor-receptor-egfr-inhibitors-for-metastatic-colorectal-cancer
#13
REVIEW
David Lok Hang Chan, Eva Segelov, Rachel Sh Wong, Annabel Smith, Rebecca A Herbertson, Bob T Li, Niall Tebbutt, Timothy Price, Nick Pavlakis
BACKGROUND: Epidermal growth factor receptor (EGFR) inhibitors prevent cell growth and have shown benefit in the treatment of metastatic colorectal cancer, whether used as single agents or in combination with chemotherapy. Clear benefit has been shown in trials of EGFR monoclonal antibodies (EGFR MAb) but not EGFR tyrosine kinase inhibitors (EGFR TKI). However, there is ongoing debate as to which patient populations gain maximum benefit from EGFR inhibition and where they should be used in the metastatic colorectal cancer treatment paradigm to maximise efficacy and minimise toxicity...
June 27, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28638455/the-prognostic-and-predictive-value-of-carbohydrate-antigen-19-9-in-metastatic-colorectal-cancer-patients-with-first-line-bevacizumab-containing-chemotherapy
#14
Chang Jiang, Shousheng Liu, Wenzhuo He, Bei Zhang, Liangping Xia
Objective: We had previously demonstrated that the carbohydrate antigen 19-9 (CA19-9), lactate dehydrogenase (LDH), neutrophil lymphocyte ratio (NLR) are prognostic factors for patients with metastatic colorectal cancer (mCRC). In this study, we try to analysis the association of these blood-based biomarkers with bevacizumab efficacy in the first line setting. Methods: A total of 284 eligible consecutive mCRC patients who received first-line chemotherapy with or without bevacizumab were studied from 2007 to 2014 at Sun Yat-Sen University Cancer Center...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28559019/il6-is-associated-with-response-to-dasatinib-and-cetuximab-phase-ii-clinical-trial-with-mechanistic-correlatives-in-cetuximab-resistant-head-and-neck-cancer
#15
L P Stabile, A M Egloff, M K Gibson, W E Gooding, J Ohr, P Zhou, N J Rothenberger, L Wang, J L Geiger, J T Flaherty, J R Grandis, J E Bauman
OBJECTIVE: Src family kinase (SFK) activation circumvents epidermal growth factor receptor (EGFR) targeting in head and neck squamous cell carcinoma (HNSCC); dual SFK-EGFR targeting could overcome cetuximab resistance. PATIENTS AND METHODS: We conducted a Simon two-stage, phase II trial of the SFK inhibitor, dasatinib, and cetuximab in biomarker-unselected patients with cetuximab-resistant, recurrent/metastatic HNSCC. Pre- and post-treatment serum levels of interleukin-6 (IL6) were measured by ELISA...
June 2017: Oral Oncology
https://www.readbyqxmd.com/read/28551660/serum-nitric-oxide-as-a-predictive-biomarker-for-bevacizumab-in-non-small-cell-lung-cancer-patients
#16
Satoshi Muto, Hironori Takagi, Yuki Owada, Takuya Inoue, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki
BACKGROUND/AIM: Reportedly, hypertension tends to be associated with response to bevacizumab therapy, because bevacizumab suppresses vascular nitric oxide production. In this study we examined the predictive value of nitric oxide in bevacizumab-treated non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Fifteen patients with advanced or recurrent NSCLC treated with bevacizumab-based regimens were evaluated retrospectively. Serum NOx (NO2(-)/NO3(-)) was assayed by the Griess method...
June 2017: Anticancer Research
https://www.readbyqxmd.com/read/28499022/quantitative-imaging-biomarkers-for-risk-stratification-of-patients-with-recurrent-glioblastoma-treated-with-bevacizumab
#17
Patrick Grossmann, Vivek Narayan, Ken Chang, Rifaquat Rahman, Lauren Abrey, David A Reardon, Lawrence H Schwartz, Patrick Y Wen, Brian M Alexander, Raymond Huang, Hugo J W L Aerts
Background: Antiangiogenic therapy with bevacizumab is the most widely used treatment option for recurrent glioblastoma, but therapeutic response varies substantially and effective biomarkers for patient selection are not available. To this end, we determine whether novel quantitative radiomic strategies on the basis of magnetic-resonance-imaging (MRI) have the potential to noninvasively stratify survival and progression in this patient population. Methods: In an initial cohort of 126 patients, we identified a distinct set of features representative of the radiographic phenotype on baseline (pre-treatment) MRI...
May 11, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28487489/apelin-a-putative-novel-predictive-biomarker-for-bevacizumab-response-in-colorectal-cancer
#18
Linda Zuurbier, Arman Rahman, Martijn Cordes, Jennifer Scheick, Tse J Wong, François Rustenburg, Jesu Christopher Joseph, Peter Dynoodt, Rory Casey, Paul Drillenburg, Michael Gerhards, Ana Barat, Rut Klinger, Bozena Fender, Darran P O'Connor, Johannes Betge, Matthias P Ebert, Timo Gaiser, Jochen H M Prehn, Arjan W Griffioen, Nicole C T van Grieken, Bauke Ylstra, Annette T Byrne, Laurens G van der Flier, William M Gallagher, Ruben Postel
Bevacizumab (bvz) is currently employed as an anti-angiogenic therapy across several cancer indications. Bvz response heterogeneity has been well documented, with only 10-15% of colorectal cancer (CRC) patients benefitting in general. For other patients, clinical efficacy is limited and side effects are significant. This reinforces the need for a robust predictive biomarker of response. To identify such a biomarker, we performed a DNA microarray-based transcriptional profiling screen with primary endothelial cells (ECs) isolated from normal and tumour colon tissues...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28465540/circulating-vegf-and-enos-variations-as-predictors-of-outcome-in-metastatic-colorectal-cancer-patients-receiving-bevacizumab
#19
Giorgia Marisi, Emanuela Scarpi, Alessandro Passardi, Oriana Nanni, Angela Ragazzini, Martina Valgiusti, Andrea Casadei Gardini, Luca Maria Neri, Giovanni Luca Frassineti, Dino Amadori, Paola Ulivi
Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, at the first clinical evaluation and at progression were available for 129 patients enrolled in the prospective multicentric ITACa trial and randomized to receive FOLFOX4/FOLFIRI (CT) with (64 patients) or without B (65 patients)...
May 2, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28451421/role-of-ras-mutation-status-as-a-prognostic-factor-for-patients-with-advanced-colorectal-cancer-treated-with-first-line-chemotherapy-based-on-fluoropyrimidines-and-oxaliplatin-with-or-without-bevavizumab-a-retrospective-analysis
#20
Javier Garde Noguera, Eloisa Jantus-Lewintre, Mireia Gil-Raga, Elena Evgenyeva, Sonia Maciá Escalante, Antonio Llombart-Cussac, Carlos Camps Herrero
The role of Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma RAS viral oncogene homolog (NRAS) mutations as negative predictors for anti-epidermal growth factor receptor (EGFR) therapies in metastatic colorectal cancer (CRC) has been firmly established. However, whether the RAS mutation status plays a role as a biomarker for anti-vascular endothelial growth factor (VEGF) treatment remains controversial. Data from 93 CRC patients who received first-line cytotoxic chemotherapy with fluoropyrimidines and oxaliplatin, with or without bevacizumab, were analyzed...
March 2017: Molecular and Clinical Oncology
keyword
keyword
93667
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"